Breast Cancer clinical trials

300 actively recruiting breast cancer trials in the United States. The most common cancer in women in the U.S. Clinical trials test new therapies for early-stage, locally advanced, and metastatic breast cancer.

Data from ClinicalTrials.gov · last refreshed 2026-05-11 · Breast Cancer stats on SEER

Phase 1

Phase 2

Phase 3

Phase 4

148

Other

Breast Cancer by the numbers (U.S.)

316,950

Estimated new cases (2025)

42,170

Estimated deaths (2025)

91.7%

5-year relative survival

Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Top trials by phase + site coverage

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Locations:

University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Anchorage Radiation Therapy Center — Anchorage, Alaska

+ 952 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT06876714

Locations:

Cancer Center at Saint Joseph's — Phoenix, Arizona
Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Mercy Hospital Fort Smith — Fort Smith, Arkansas

+ 624 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03418961

Locations:

Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Alaska Breast Care and Surgery LLC — Anchorage, Alaska
Alaska Oncology and Hematology LLC — Anchorage, Alaska

+ 574 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of r…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT03488693

Locations:

Fairbanks Memorial Hospital — Fairbanks, Alaska
Banner MD Anderson Cancer Center — Gilbert, Arizona
Banner-University Medical Center Phoenix — Phoenix, Arizona

+ 446 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology

NCT ID: NCT06748222

Locations:

Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Mercy Hospital Fort Smith — Fort Smith, Arkansas
Kaiser Permanente-Deer Valley Medical Center — Antioch, California

+ 294 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology

NCT ID: NCT06500455

Locations:

Banner University Medical Center - Tucson — Tucson, Arizona
University of Arizona Cancer Center-North Campus — Tucson, Arizona
University of Arkansas for Medical Sciences — Little Rock, Arkansas

+ 253 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…

Sponsor: Eli Lilly and Company

NCT ID: NCT07174336

Locations:

Alaska Oncology and Hematology — Anchorage, Alaska
Ironwood Cancer & Research Centers — Chandler, Arizona
Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona

+ 107 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…

Sponsor: Pfizer

NCT ID: NCT07062965

Locations:

Ironwood Cancer & Research Centers — Chandler, Arizona
Ironwood Cancer & Research Centers — Gilbert, Arizona
Ironwood Cancer & Research Centers — Glendale, Arizona

+ 99 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…

Sponsor: Novartis Pharmaceuticals

NCT ID: NCT05827081

Locations:

Central Alabama Research — Birmingham, Alabama
Alaska Oncology and Hematology LLC — Anchorage, Alaska
Western Reg MC-COH Phoenix — Goodyear, Arizona

+ 69 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…

Sponsor: American Society of Clinical Oncology

NCT ID: NCT06377852

Locations:

Ironwood Cancer & Research Centers — Chandler, Arizona
Ironwood Cancer & Research Centers — Gilbert, Arizona
Ironwood Cancer & Research Centers — Glendale, Arizona

+ 64 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…

Sponsor: Jazz Pharmaceuticals

NCT ID: NCT06435429

Locations:

Mayo Clinic Scottsdale - PPDS — Phoenix, Arizona
Arizona Oncology Tucson - Wilmot — Tucson, Arizona
University of Arizona Cancer Center — Tucson, Arizona

+ 45 more sites in the U.S.

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…

Sponsor: BioNTech SE

NCT ID: NCT07173751

Locations:

Highlands Oncology Group — Springdale, Arkansas
Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center — Palo Alto, California
Cancer Care Specialists — Decatur, Illinois

+ 17 more sites in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

How to read clinical trial eligibility →

Inclusion, exclusion, biomarker requirements, performance status, and prior-therapy rules.

How to find a clinical trial →

Search strategy, matching services, and when to involve your oncologist.

Clinical trial phases explained →

Phase 1 through 4, what each means for patients.

Insurance coverage for clinical trials →

The ACA requires coverage of routine patient costs. How to appeal denials.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-11

Breast Cancer clinical trials

Breast Cancer by the numbers (U.S.)

Browse breast cancer trials by state

Top trials by phase + site coverage

Before you contact a trial site